Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure

By sjmartinez • April 8, 2025

Anderson E, Choi Y, Buchsbaum RJ, Klein A, Ky B, Landsburg D, Durani U, Ruddy KJ, Yu AF, Leong D, Asnani A, Neilan TG, Ganatra S, Bloom M, Barac A, Yang EH, Deswal A, Cheng RK, Weiss M, Evens AM, Kahl B, Friedberg JW, Parsons SK, Upshaw JN. Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Apr 8:1-10. doi: 10.1080/10428194.2025.2484367. Epub ahead of print. PMID: 40195874.

Tags: anthracycline, Cancer, Cancer survivorship, Cardiology/Epi, cardiomyopathy, cardioprotection, heart failure, Publications

National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Keykhaei M, Sandhu AT, Hsue PY, Greene SJ, Ziaeian B, Kittleson M, Villarreal-Gonzalez M, Hallaj S, Ramsis M, Agarwal MA, Fonarow GC. National Impact of[...]

Cardioprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors: What Have We Learned So Far?

Qi L, Wright EM, Cai X. Cardioprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors: What Have We Learned So Far? JACC Adv. 2026 Aug 4;5(9):103095. doi: 10.1016/j.jacadv.2026.103095.[...]

Lung Function after Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcomes Study (DPPOS)

Pistenmaa CL, Doherty L, Hermann EA, Brown AL, Dabelea D, Holguin F, Watson K, Knowler WC, Temprosa M, Barr RG; DPP Research Group. Lung Function[...]